Simon Kraler and Colleagues’ New Work on JCAD: Targeting Impaired Fibrinolysis to Address Post-ACS Residual Risk
Simon Kraler, ESC Young Cardiovascular Professionals Committee Member at European Society of Cardiology, posted on LinkedIn:
“Residual risk: is it time to move beyond LDL-c and inflammation?
Despite guideline-directed lipid lowering and anti-inflammatory therapy, patients with a recent ACS remain at 𝐯𝐞𝐫𝐲 𝐡𝐢𝐠𝐡 𝐢𝐬𝐜𝐡𝐚𝐞𝐦𝐢𝐜 𝐫𝐢𝐬𝐤.
Based on GWAS and mechanistic data, we hypothesized that JCAD (‘Junctional Protein Associated with Coronary Artery Disease’) on chromosome 10 might represent the missing link.
In our newly published European Heart Journal study, JCAD independently predicted 1-year MACE in patients with residual lipid risk, inflammatory risk, or both – notably independent of LDL-c and hs-CRP
JCAD = impaired endogenous fibrinolysis and high MACE risk, with similar results obtained during external validation.
JCAD may represent a novel therapeutic target to address residual risk after a recent ACS.
Title: The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk
Authors: Simon Kraler, Luca Liberale, Amedeo Tirandi, Margherita Moriero, Yifan Wang, Mohamed Farag, Federico Carbone, Maria B Bertolotto, Valentina Pusterla, Davide Ramoni, Stefano Ministrini, Yustina M Puspitasari, Francesco Bruno, Lorenz Räber, Davide Di Vece, Christian Templin, Olivier Muller, François Mach, Filippo Crea, Giovanni G Camici, Tetiana Lapikova-Bryhinska, Alexander Akhmedov, Arnold von Eckardstein, Diana A Gorog, Fabrizio Montecucco, Thomas F Lüscher
Special thanks to the colleagues and friends at University of Genoa, King’s College London, University of Zurich, CHUV | Lausanne university hospital, Universitätsspital Zürich, HUG – Hopitaux Universitaires de Genève and Insel Gruppe.
Thank you Thomas F. Lüscher, Luca Liberale, Giovanni G Camici, Diana Gorog, Lorenz Räber, Davide Di Vece, Yifan Wang, Francesco Bruno and all!”
Discover the latest in Hemostasis Today.
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT
-
Jul 2, 2026, 18:47Vee Townsend: IMHUE Highlights 9 Myths and Facts About Hemophilia B
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association